MedTrace Logo

Dose Escalating Study of BPI-3016 in Healthy Subjects

NCT03188848 · Status: UNKNOWN · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 63

Last updated 2019-01-02

No results posted yet for this study

Summary

This is a randomized, double-blind, placebo-controlled, dose finding study evaluating the safety, pharmacokinetics and pharmacodynamics of subcutaneously injected BPI-3016 in Chinese healthy subjects.

Conditions

  • Healthy Subject

Interventions

DRUG

BPI-3016

Single-dose subcutaneous injection of BPI-3016

DRUG

Placebo

Single-dose subcutaneous injection of placebo to match BPI-3016

Sponsors & Collaborators

  • Betta Pharmaceuticals Co., Ltd.

    lead INDUSTRY

Principal Investigators

  • Kexin Li · Beijing Hospital

  • Lixin Guo · Beijing Hospital

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
TRIPLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
45 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2017-05-24
Primary Completion
2019-07-31
Completion
2019-12-31

Countries

  • China

Study Locations

More Related Trials

Entities

Drugs

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT03188848 on ClinicalTrials.gov